Fibrosis
is when connective tissue from an injury or other circumstances thickens and
scars, or when there is excess fibrous connective tissue in an organ after it
has been exposed to a chronic disease. Unfortunately, the effects of fibrosis
cannot be reversed, and there is currently no treatment that stops the disease
from getting worse, although some treatments can deal with the symptoms
temporarily.
Galectin
Therapeutics, Inc. (NASDAQ: GALT) is currently undertaking its phase 2a pilot
trial (NASHFX) with GR-MD-02 in non-alcoholic steatohepatitis (NASH) patients
with advanced fibrosis. Although the study did not meet original expectations,
Galectin’s larger scale, one year trial in patients with NASH cirrhosis has
already enrolled 162 subjects, and top line results will be reported by the end
of December 2017. The company considers it encouraging to see that GR-MD-02 has
an important clinical effect in both moderate and severe cases of psoriasis.
This further suggests that the substance can play a role for human diseases
that could be related to NASH.
Galectin
Therapeutics, Inc. is a biotechnology company focused on the science of
galectins, a family of proteins, and drug development. With this expertise, the
company creates new therapies for patients suffering from fibrotic diseases and
cancer. Galectin works with a variety of partners in order to achieve cost
effective and efficient development results within short time frames.
GALT
is currently looking to enhance and market its lead compounds in liver fibrosis
and cancer immunotherapies. The company has three key areas of focus: studying
galectins, developing proprietary compounds for diseases, and advancing its
discovery programs. All three work together in order to achieve the overall
goal of creating new therapies for fibrotic diseases and cancer.
For
more information, visit www.GalectinTherapeutics.com
About
MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
